Zhejiang East Asia Pharmaceutical Co. Ltd.
Zhejiang East Asia Pharmaceutical Co., Ltd. produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents… Read more
Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.57 Billion CNY
Based on the latest financial reports, Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) has total liabilities worth CN¥1.57 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang East Asia Pharmaceutical Co. Ltd. - Total Liabilities Trend (2016–2024)
This chart illustrates how Zhejiang East Asia Pharmaceutical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang East Asia Pharmaceutical Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Zhejiang East Asia Pharmaceutical Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BCEG Environmental Remediation Co. Ltd.
SHE:300958
|
China | CN¥1.49 Billion |
|
Bajaj Hindusthan Sugar Limited
NSE:BAJAJHIND
|
India | ₹86.92 Billion |
|
LUBAWA SA
WAR:LBW
|
Poland | zł151.17 Million |
|
Greaves Cotton Limited
NSE:GREAVESCOT
|
India | ₹10.18 Billion |
|
Guangdong AVCiT Tech Hldg Co
SHE:001229
|
China | CN¥70.03 Million |
|
Addcn Technology Co Ltd
TWO:5287
|
Taiwan | NT$1.79 Billion |
|
Aeluma, Inc
NASDAQ:ALMU
|
USA | $1.77 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Zhejiang East Asia Pharmaceutical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang East Asia Pharmaceutical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang East Asia Pharmaceutical Co. Ltd. (2016–2024)
The table below shows the annual total liabilities of Zhejiang East Asia Pharmaceutical Co. Ltd. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.68 Billion | +26.64% |
| 2023-12-31 | CN¥1.33 Billion | +110.28% |
| 2022-12-31 | CN¥631.57 Million | +28.11% |
| 2021-12-31 | CN¥492.99 Million | +40.14% |
| 2020-12-31 | CN¥351.79 Million | +36.06% |
| 2019-12-31 | CN¥258.55 Million | -32.47% |
| 2018-12-31 | CN¥382.88 Million | -28.25% |
| 2017-12-31 | CN¥533.63 Million | -11.02% |
| 2016-12-31 | CN¥599.74 Million | -- |